April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Anti-Pneumolysin Immunoglobulin as Adjunctive Treatment for Streptococcus pneumoniae Endophthalmitis in Rabbits
Author Affiliations & Notes
  • D. A. Ghate
    Ophthalmology,
    University of Mississippi Medical Center, Jackson, Mississippi
  • M. Sanders
    Microbiology,
    University of Mississippi Medical Center, Jackson, Mississippi
  • Z. M. Robertson
    Ophthalmology,
    University of Mississippi Medical Center, Jackson, Mississippi
  • J. Fratkin
    Pathology,
    University of Mississippi Medical Center, Jackson, Mississippi
  • A. Smith
    Ophthalmology,
    University of Mississippi Medical Center, Jackson, Mississippi
  • M. Marquart
    Microbiology,
    University of Mississippi Medical Center, Jackson, Mississippi
  • C. Chen
    Ophthalmology,
    University of Mississippi Medical Center, Jackson, Mississippi
  • Footnotes
    Commercial Relationships  D.A. Ghate, None; M. Sanders, None; Z.M. Robertson, None; J. Fratkin, None; A. Smith, None; M. Marquart, None; C. Chen, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5111. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. A. Ghate, M. Sanders, Z. M. Robertson, J. Fratkin, A. Smith, M. Marquart, C. Chen; Anti-Pneumolysin Immunoglobulin as Adjunctive Treatment for Streptococcus pneumoniae Endophthalmitis in Rabbits. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5111.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine ocular tolerance of intravitreal anti-pneumolysin IgG immunoglobin (ab-PLY) and its efficacy as an adjunct to intravitreal vancomycin in experimental Streptococcus pneumoniae endophthalmitis.

Methods: : Ab-PLY was isolated from the serum of New Zealand white (NZW) rabbits immunized with heat inactivated pneumolysin. IgG titers against PLY were determined by ELISA. The ab-PLY was run on a gel to rule out contamination. Rabbits were treated with intravitreal ab-PLY, 400 µg (n=6) and 200 µg (n=3) and sham intravitreal injections with either PBS or vancomycin (n=4). In the infection group, E353 strain of S. pneumoniae (102 CFU/10µl) was injected intravitreally into one eye of each animal. 24 hours later, the rabbits were divided into 3 groups; V gp (1mg/0.1 ml intravitreal vancomycin: n=3); V/ab-PLY gp (intravitreal vancomycin + 200 µg ab-PLY: n=3) and control (untreated: n=3). Animals had daily slit lamp examination and dilated indirect ophthalmoscopy and were euthanized on day 3 post infection (PI). Electroretinograms (ERG) were done on days 0 and 3 PI. Vitreous aspirate was diluted and plated on blood agar on day 3 PI.

Results: : Sham injections caused no clinical reaction. Intravitreal ab-PLY caused severe fibrinous anterior chamber (AC) reaction and inferior vitreous exudates (400 µg >>200 µg).Histopathology (HPE) showed vitreous inflammatory cells without retinal damage. Controls developed panophthalmitis by day 3 PI. Treated eyes improved. AC and vitreous inflammation was more severe in the V/ab-PLY gp compared to V gp on all days. HPE showed that the V/ab-PLY gp had increased vitreous and AC inflammatory cells compared to V gp but had similar retinal damage. ERG amplitude was similar between the 2 treatment groups.

Conclusions: : Intravitreal ab-PLY caused an ocular inflammatory reaction without structural or functional retinal damage. In experimental S. pneumoniae endophthalmitis, adjunctive intravitreal ab-PLY did not provide additional therapeutic benefits (evaluated by clinical examination, ERG, microbiology and HPE) compared to intravitreal vancomycin alone.

Keywords: endophthalmitis • bacterial disease • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×